Design of a folding inhibitor of the HIV-1 protease

被引：2
|
作者：
Tiana, G
Broglia, RA
Sutto, L
Provasi, D
机构：
[1] Univ Milan, Dipartimento Fis, I-20133 Milan, Italy
[2] Ist Nazl Fis Nucl, I-20133 Milan, Italy
[3] Univ Copenhagen, Niels Bohr Inst, DK-2100 Copenhagen, Denmark
来源：
MOLECULAR SIMULATION | 2005年 / 31卷 / 11期
关键词：
HIV-1; protease; Monte Carlo simulations; local elementary structures; HIV-PR monomer;
D O I：
10.1080/089270500262721
中图分类号：
O64 [物理化学（理论化学）、化学物理学];
学科分类号：
070304 ; 081704 ;
摘要：
A novel way to inhibit HIV-1 protease by destabilizing its native state is discussed. A simplified protein model is used together with Monte Carlo simulations, to assess the destabilizing effect of peptides displaying the same sequence as specific fragments of the protein which are essential for its stability. Model calculations also show that it is unlikely that the protein can escape the inhibitory peptide by point mutations.
引用
收藏
页码：765 / 771
页数：7
相关论文
共 50 条
  • [41] Inhibition of HIV-2 protease by HIV-1 protease inhibitors in clinical use
    Brower, Evan T.
    Bacha, Usman M.
    Kawasaki, Yuko
    Freire, Ernesto
    CHEMICAL BIOLOGY & DRUG DESIGN, 2008, 71 (04) : 298 - 305
  • [42] Thermodynamic dissection of the binding energetics of KNI-272, a potent HIV-1 protease inhibitor
    Velazquez-Campoy, A
    Luque, I
    Todd, MJ
    Milutinovich, M
    Kiso, Y
    Freire, E
    PROTEIN SCIENCE, 2000, 9 (09) : 1801 - 1809
  • [43] SOLVENT ACCESSIBILITY AS A PREDICTIVE TOOL FOR THE FREE-ENERGY OF INHIBITOR BINDING TO THE HIV-1 PROTEASE
    NAUCHITEL, V
    VILLAVERDE, MC
    SUSSMAN, F
    PROTEIN SCIENCE, 1995, 4 (07) : 1356 - 1364
  • [44] HIV-1 Protease as DNA Immunogen against Drug Resistance in HIV-1 Infection: DNA Immunization with Drug Resistant HIV-1 Protease Protects Mice from Challenge with Protease-Expressing Cells
    Petkov, Stefan
    Kilpelaeinen, Athina
    Bayurova, Ekaterina
    Latanova, Anastasia
    Mezale, Dzeina
    Fridrihsone, Ilse
    Starodubova, Elizaveta
    Jansons, Juris
    Dudorova, Alesja
    Gordeychuk, Ilya
    Wahren, Britta
    Isaguliants, Maria
    CANCERS, 2023, 15 (01)
  • [45] Evolutionary analysis of HIV-1 protease inhibitors: Methods for design of inhibitors that evade resistance
    Stoffler, D
    Sanner, MF
    Morris, GM
    Olson, AJ
    Goodsell, DS
    PROTEINS-STRUCTURE FUNCTION AND GENETICS, 2002, 48 (01): : 63 - 74
  • [46] Coevolution and subsite decomposition for the design of resistance-evading HIV-1 protease inhibitors
    Rosin, CD
    Belew, RK
    Walker, WL
    Morris, GM
    Olson, AJ
    Goodsell, DS
    JOURNAL OF MOLECULAR BIOLOGY, 1999, 287 (01) : 77 - 92
  • [47] HIV-1 protease inhibitors and mechanisms of HIV-1's resistance
    Das, Debananda
    GLOBAL HEALTH & MEDICINE, 2024, 6 (06): : 357 - 362
  • [48] Ritonavir-boosted protease inhibitor monotherapy for the treatment of HIV-1 infection
    Sahali, Sabrinel
    Chaix, Marie-Laure
    Delfraissy, Jean-Francois
    Ghosn, Jade
    AIDS REVIEWS, 2008, 10 (01) : 4 - 14
  • [49] In Vivo Emergence of a Novel Protease Inhibitor Resistance Signature in HIV-1 Matrix
    Datir, Rawlings
    Kemp, Steven
    El Bouzidi, Kate
    Mlchocova, Petra
    Goldstein, Richard
    Breuer, Judy
    Towers, Greg J.
    Jolly, Clare
    Quinones-Mateu, Miguel E.
    Dakum, Patrick S.
    Ndembi, Nicaise
    Gupta, Ravindra K.
    MBIO, 2020, 11 (06): : 1 - 15
  • [50] SYNERGISTIC DRUG-INTERACTIONS OF AN HIV-1 PROTEASE INHIBITOR WITH AZT IN DIFFERENT IN-VITRO MODELS OF HIV-1 INFECTION
    LAMBERT, DM
    BARTUS, H
    FERNANDEZ, AV
    BRATBYANDERS, C
    LEARY, JJ
    DREYER, GB
    METCALF, BW
    PETTEWAY, SR
    ANTIVIRAL RESEARCH, 1993, 21 (04) : 327 - 342
12345